-
1.发明申请公开(公告)号：US20210024647A1
公开(公告)日：2021-01-28
申请号：US17066190
申请日：2020-10-08
Applicant: GENMAB HOLDING B.V.
Inventor： Simone OOSTINDIE , Frank BEURSKENS , Esther BREIJ , Edward VAN DEN BRINK , Andreas HOLLENSTEIN , Marije OVERDIJK , Margaret LINDORFER , Ronald TAYLOR , Paul PARREN , Hilma VAN DER HORST , Martine E.D. CHAMULEAU , Tuna MUTIS
Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
-
公开(公告)号：US12275797B2
公开(公告)日：2025-04-15
申请号：US17253276
申请日：2019-06-24
Applicant: GENMAB HOLDING B.V.
Inventor： Simone Oostindie , Frank Beurskens , Ronald Taylor , Margaret Lindorfer , Hilma Van Der Horst , Martine E. D. Chamuleau , Tuna Mutis , Paul Parren , Esther Breij
IPC: A61K39/395 , A61K45/06 , C07K16/28
Abstract: The present invention relates to anti-CD37antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG, for use as a medicament in combination with anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG. The invention also relates to a novel composition of anti-CD37 antibodies having an Fc-Fc 5 interaction enhancing substitution and anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution. In particular, the invention relates to compositions wherein the anti-CD37 antibody binds human CD37 and the anti-CD20 antibody binds human CD20. The invention also relates to compositions where the composition is a pharmaceutical composition and the use of such compositions in treatment of cancer and other diseases.
-
3.发明申请公开(公告)号：US20210355232A1
公开(公告)日：2021-11-18
申请号：US17382758
申请日：2021-07-22
Applicant: GENMAB HOLDING B.V.
Inventor： Simone OOSTINDIE , Frank BEURSKENS , Esther BREIJ , Edward VAN DEN BRINK , Andreas HOLLENSTEIN , Marije OVERDIJK , Margaret LINDORFER , Ronald TAYLOR , Paul PARREN , Hilma VAN DER HORST , Martine E.D. CHAMULEAU , Tuna MUTIS
Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
-
4.发明申请公开(公告)号：US20200291124A1
公开(公告)日：2020-09-17
申请号：US16872140
申请日：2020-05-11
Applicant: GENMAB HOLDING B.V.
Inventor： Simone OOSTINDIE , Frank BEURSKENS , Esther BREIJ , Edward VAN DEN BRINK , Andreas HOLLENSTEIN , Marije OVERDIJK , Margaret LINDORFER , Ronald TAYLOR , Paul PARREN , Hilma VAN DER HORST , Martine E.D. CHAMULEAU , Tuna MUTIS
Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
-
5.发明公开公开(公告)号：US20240117064A1
公开(公告)日：2024-04-11
申请号：US17975362
申请日：2022-10-27
Applicant: GENMAB HOLDING B.V.
Inventor： Simone OOSTINDIE , Frank BEURSKENS , Esther BREIJ , Edward VAN DEN BRINK , Andreas HOLLENSTEIN , Marije OVERDIJK , Margaret LINDORFER , Ronald TAYLOR , Paul PARREN , Hilma VAN DER HORST , Martine E.D. CHAMULEAU , Tuna MUTIS
CPC classification number: C07K16/2896 , A61K49/00 , A61P35/00 , C07K16/2887 , G01N33/68 , A61K2039/505
Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
-
Patent Agency Ranking
6.发明公开公开(公告)号：US20230399414A1
公开(公告)日：2023-12-14
申请号：US17975333
申请日：2022-10-27
Applicant: GENMAB HOLDING B.V,
Inventor： Simone OOSTINDIE , Frank BEURSKENS , Esther BREIJ , Edward VAN DEN BRINK , Andreas HOLLENSTEIN , Marije OVERDIJK , Margaret LINDORFER , Ronald TAYLOR , Paul PARREN , Hilma VAN DER HORST , Martine E.D.CHAMULEAU , Tuna MUTIS
CPC classification number: C07K16/2896 , A61P35/00 , A61K49/00 , C07K16/2887 , G01N33/68 , A61K2039/505
Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
-
公开(公告)号：US20210371539A1
公开(公告)日：2021-12-02
申请号：US17253276
申请日：2019-06-24
Applicant: GENMAB HOLDING B.V.
Inventor： Simone OOSTINDIE , Frank BEURSKENS , Ronald TAYLOR , Margaret LINDORFER , Hilma VAN DER HORST , Martine E. D. CHAMULEAU , Tuna MUTIS , Paul PARREN , Esther BREIJ
Abstract: The present invention relates to anti-CD37antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG, for use as a medicament in combination with anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG. The invention also relates to a novel composition of anti-CD37 antibodies having an Fc-Fc 5 interaction enhancing substitution and anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution. In particular, the invention relates to compositions wherein the anti-CD37 antibody binds human CD37 and the anti-CD20 antibody binds human CD20. The invention also relates to compositions where the composition is a pharmaceutical composition and the use of such compositions in treatment of cancer and other diseases.
-
8.发明公开公开(公告)号：US20240076397A1
公开(公告)日：2024-03-07
申请号：US17975353
申请日：2023-10-27
Applicant: GENMAB HOLDING B.V.
Inventor： Simone OOSTINDIE , Frank BEURSKENS , Esther BREIJ , Edward VAN DEN BRINK , Andreas HOLLENSTEIN , Marije OVERDIJK , Margaret LINDORFER , Ronald TAYLOR , Paul PARREN , Hilma VAN DER HORST , Martine E.D. CHAMULEAU , Tuna MUTIS
CPC classification number: C07K16/2896 , A61K49/00 , A61P35/00 , C07K16/2887 , G01N33/68 , A61K2039/505
Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
-
9.发明申请公开(公告)号：US20200270359A1
公开(公告)日：2020-08-27
申请号：US16498104
申请日：2018-04-03
Applicant: GENMAB HOLDING B.V.
Inventor： Simone OOSTINDIE , Frank BEURSKENS , Esther BREIJ , Edward VAN DEN BRINK , Andreas HOLLENSTEIN , Marije OVERDIJK , Margaret LINDORFER , Ronald TAYLOR , Paul PARREN , Hilma VAN DER HORST , Martine E.D. CHAMULEAU , Tuna MUTIS
Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
-
公开(公告)号：US20240252635A1
公开(公告)日：2024-08-01
申请号：US17281724
申请日：2019-10-04
Applicant: GENMAB HOLDING B.V.
Inventor： Simone OOSTINDIE , Frank BEURSKENS , Esther C. W. BREIJ , Edward N. VAN DEN BRINK , Andreas HOLLENSTEIN , Marije OVERDIJK , Margaret LINDORFER , Ronald TAYLOR , Paul PARREN , Hilma VAN DER HORST , Martine E. D. CHAMULEAU , Tuna MUTIS , Christian CIMANDER , Martin SAHLIN , Shan REN , Abbas RAZVI , Christoph GRAPENTIN
CPC classification number: A61K39/39591 , A61K47/02 , A61K47/183 , A61K47/22 , A61K47/26 , A61P35/02 , C07K16/2887 , C07K16/2896 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/732 , C07K2317/734
Abstract: The disclosure relates to pharmaceutical compositions comprising CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The disclosure also relates to use of these pharmaceutical compositions for the treatment of cancer and other diseases.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.013 seconds)
